黄芪注射液对急性白血病化疗患儿造血和免疫功能的影响
|
摘要
目的：探讨黄芪注射液对急性淋巴细胞白血病化疗患儿造血功能和免疫功能的影响。方法：63例均处于初治诱导缓解治疗阶段的急性淋巴细胞白血病患儿随机分为治疗组31例和对照组32例,治疗组在化疗同时给予黄芪注射液0.5～1ml/kg/d,共35天,对照组单用化疗,两组其他支持治疗相同。观察两组化疗后完全缓解率,化疗前后WBC、RBC、HB、PLT, T淋巴细胞亚群CD3+、CD4+ CD8+、CD4+/CD8+比值、和NK细胞的水平,感染及抗生素应用天数。结果：化疗后完全缓解率治疗组[84%(26/31)]与对照组[75%(24/32)]比较,差异无统计学意义(P>0.05)；化疗后治疗组外周血血小板计数和血红蛋白均高于对照组,差异有统计学意义(P<0.05)；化疗后两组CD3+、CD4+、CD8+明显高于化疗前,差异有统计学意义(P<0.05)；化疗后治疗组CD3+、CD4+/CD8+比值明显高于对照组,差异有统计学意义(P<0.05)；化疗期间并发感染在使用抗生素天数方面治疗组明显少于对照组,两组比较差异有统计学意义(P<0.05)。结论：黄芪注射液能减轻化疗对急性淋巴细胞白血病患儿骨髓造血功能的抑制,并能促进化疗患儿骨髓造血功能的恢复；提高化疗患儿的细胞免疫功能；且化疗期间并发感染的程度轻,抗生素应用天数少,感染容易得到控制,可改善急性白血病化疗患儿的生活质量。
Objective:To investigate the effect of A.membranceus injection for hemopoietic and immune function reconstruction in children with acute leukemia after chemotherapy. Methods:Sixty-three leukemia children at remission inducing stage of initial treatment were randomly assigned to two groups,the reatment group treated with A.membranceus (0.5～1ml/kg/daily)plus chenmotherapy and the contorl group only treated with chemotherapy for 35 days,with same supportive treatments administered to both.Levels of blood routine test,T lymphocyte subsets(CD3+ CD4+、CD8+、CD4+/CD8+)and NK cell were detemined before and after treatment, and the remission rate was assessed after treatment.Results:The remission rates in the two groups showed no significant difference[84%(26/31) vs 75%(24/32),(P>0.05)] statistically.Levels of peripheral leucocyte count and hemoglobin as well as levels of CD3+、CD4+/CD8+ were significantly higher in the treatment group than in the control group (P<0.05),but no significant difference was shown between groups in CD4+、CD8+、NK cell level. Conclusion:A.membranceus can lighten the inhibition of chemotherapy on hemopoietic function of pone marrow and promote its recovery,enhance the immune function, Moreover the patients of the A.membranceus treated group suffered fewer infections which could be controlled more easily also with decreased administration days of antibioticse and improve the quality of life in atients with acute leukemia undergoing chemotherapy.
Objective:To investigate the effect of A.membranceus injection for hemopoietic and immune function reconstruction in children with acute leukemia after chemotherapy. Methods:Sixty-three leukemia children at remission inducing stage of initial treatment were randomly assigned to two groups,the reatment group treated with A.membranceus (0.5～1ml/kg/daily)plus chenmotherapy and the contorl group only treated with chemotherapy for 35 days,with same supportive treatments administered to both.Levels of blood routine test,T lymphocyte subsets(CD3+ CD4+、CD8+、CD4+/CD8+)and NK cell were detemined before and after treatment, and the remission rate was assessed after treatment.Results:The remission rates in the two groups showed no significant difference[84%(26/31) vs 75%(24/32),(P>0.05)] statistically.Levels of peripheral leucocyte count and hemoglobin as well as levels of CD3+、CD4+/CD8+ were significantly higher in the treatment group than in the control group (P<0.05),but no significant difference was shown between groups in CD4+、CD8+、NK cell level. Conclusion:A.membranceus can lighten the inhibition of chemotherapy on hemopoietic function of pone marrow and promote its recovery,enhance the immune function, Moreover the patients of the A.membranceus treated group suffered fewer infections which could be controlled more easily also with decreased administration days of antibioticse and improve the quality of life in atients with acute leukemia undergoing chemotherapy.
引文
[1]沈志祥,欧阳仁荣主编.血液肿瘤学[M].北京：人民卫生出版社,1999,523-535.
[2]Pui CH,Campana D,Evans WE.Childhood aeute lymphoblastie leukaemia-current Statusand future perspectives[J].Laneet Onco,2001,2:597-607.
[3]Schrappe M,Reiter A,Zimmermann M,et al.Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study groupfrom 1981 to 1995[J].Leukemia,2000,14:2205-2222.
[4]Metzger ML,Howard SC,Ligia CF,et al.Out come of childhood aeute hoblastic ly-mpleukaemia in resouree-poor countries[J].Laneet,2003,362:706-708.
[5]Eden T,Pui CH,Sehrappe M,etal.All children have a right to full aeeess to Treatm-ent for eaneer[J].Lancet,2004,364:1121-1122.
[6]Lilleyman J.Simple deliverable the rapy needed for childhood leukaemia[J].Lanc-et,2003,36(2):676-677.
[7]Pui CH,Relling MV,Doing JR.Aeute lymphoblastie leukaemia[J].NEng Med, 2004,350:1535-1548.
[8]Nandakumar A,Anantha N,Venugopal T,et al.Descriptive epidemiology of Lymp-hoid and haemopoietic malignaneies in Bangalore,India[J].Int Cancer,1995,63: 37-42.
[9]Howard SC,Pedrosa M,Lins M,etal.Establishment of a Pediatric oneology and Pr-ogram out comes of childhood aeute lymphoblastie leukemia in a resourcepoor a-rea[J].JAMA,2004,291:2471-2475.
[10]郑胡铺.儿童急性淋巴细胞白血病治疗进展[J].实用儿科临床杂志,2007,22(3)：167-169.
[11]Mazur B,Szczepa ski T,Karpe J,et al. Decreased numbers of CD4+T lymphocytes in peripheral blood aftertreatment of childhood acute lymphoblastic leukemia[J]. Leuk Res,2006,30(1):33-36.
[12]Winiek NJ,Carroll WL,Hunger SP.Childhood leukemia new advances and chall-enges[J].The New England Journal of Medieine,2004,351(6):601-603.
[13]苏凤哲.中医药治疗急性白血病临床探讨[J].世界中西医结合杂志,2007,2(8)：435-437.
[14]Kosmidis S, Baka M, Bouhoutsou D, et al. Longitudinal assessment of immunol-ogical status and rate of immune recovery following treatment in children with ALL[J],Pediatr Blood Cancer,2008,50(3):528-532.
[15]朱小玉,张祥忠,钟雪云,等.参芪扶正注射液对恶性肿瘤化疗患者造血及免疫功能的影响[J].中国中西医结合杂志,2010,30(2)：205-207.
[16]Pui CH,EvansWE.Treatment of acute lymphoblastie leukemia[J].NEng Med,200-6,354:166-178.
[17]Armitage JO.Tsrgeted therapy and hematological malignaney[J].Target Oncol,2-009,4(1):1-2.
[18]Lee JJ,Kook H,Park MS,et al.Immunotherapy using autologous monoeylederived dendritic cell spulsed with leukemie cell lysates for acute myeloid leukemia rel-apse after autologous peripheral blood stem cell transplantation[J].Clin Aphere-sis,2004,19(3):66-70.
[19]CHEN Guohui, HUANG Wenfeng.Progress in pharmacological effects of compo-sitions of As tragalusmembranaceus Chinese Journal of New Drugs[J].2008,17(1): 1482-1485.
[20]张冬青,汪德清.黄芪总黄酮生物学活性作用研究进展[J].中国中药杂志,2010,35(2)：253-256.
[21]蔡莉.黄芪多糖研究现状与进展[J].中国肿瘤临床,2007,34(15)：896-899.
[22]孔令梅.黄芪的免疫调节作用[J].内蒙古医学杂志,2007,39(1)：74-78.
[23]刘莎,符州.黄芪的免疫调节作用及临床应用[J].国际中医中药杂志,2006,28(4)：203-205.
[24]董菊,吕海燕,毛静娥等.黄芪注射液在肿瘤化疗中增效减毒作用的Meta分析[J].中医药,2010,16(3)：87-92.
[25]赵美蓉,周洁.黄芪多糖对恶性肿瘤化疗后骨髓抑制的影响[J].天津中医药.2007,24(2)：114-115.
[26]蔡莉,朱江.黄芪多糖研究现状与进展[J].中国肿瘤临床,2007,34(15)：896-900.
[27]汪德清,沈文梅,田亚平等.黄芪提取成分对氧自由基作用的影响[J].中国药理学通报,1994,10(2)：129-132.
[28]洪介民,王培训,邱健行等.黄芪多糖对小鼠巨核系祖细胞的影响[J].中药新药与临床药理,1998,9(3)：161-163.
[29]夏星,申萍,严翠娥等.黄芪多糖在长期骨髓细胞培养中支持体外造血的作用[J].中国中医药信息杂志,2003,10(4)：27-28.
[30]翁玲,刘学英,刘彦等.黄芪多糖对小鼠骨髓及外周血造血干细胞的增殖及动员作用[J].基础医学与临床,2003,23(3)：306-309.
[31]张仲平,洪介民.黄芪多糖对体外人骨髓造血细胞生成的影响[J].中药药理与临 床,2000,16(1)：16-17.
[32]哈敏文,李振,何安光等.黄芪合剂防治化疗性骨髓抑制的实验研究[J].中国医科大学报,1997,26(5)：449-452.
[33]袁万青,田涛.黄芪注射液配合化疗治疗白血病52例[J].陕西中医,2008,29(12)：1622.
[34]邓成珊主编.当代中西医结合血液病学[M].北京：中国医药科技出版社,1997：362.
[35]黄智芬.黄芪注射液配合西药治疗肿瘤化疗后血小板减少症30例[J].中国中医药科技,2010,23(1)：17.
[36]Pession A,Rondelli R,Basso G, et al.Treatment and long-term results in children with acute myeloid leukemia treated according to the AIEOPAML protocols Leukemia[J].2005,19:2043-2053
[37]韩晓红,石远凯,冯奉仪等.流式细胞术分析肿瘤患者免疫功能变化[J].实用肿瘤杂志,1999,14(5)：273-275.
[38]Cho WC,Leung KN.In vitro and in vivo immuno-modulating and immuno res-torative effects of Astragalusmembra naceus[J].Ethnopharmacology.2007,113(1): 132-141.
[39]Deepak PA,et al.Cancer Immunol Immunother tumor immunotherapy[J],2006,55: 1135.
[40]曹琰,严媚.小儿急性白血病治疗前后机体细胞免疫的变化[J].中国小儿血液与肿瘤杂志,2009,14(2)：82-84.
[41]王栓秀,王福禄.黄芪多糖对机体细胞免疫应答影响的研究进展[J].现代中西医结合杂志,2008,17(28)：4505-4506.
[42]刘莎.黄芪的免疫调节作用及临床应用[J].国际中医中药杂志,2006,28,(4)：203.
[43]姚金凤,王志新,张晓勇等.黄芪多糖对小鼠腹腔巨噬细胞免珠抑瘤作用及其机制[J].中国医院药学杂志,2005,25(10)：923.
[44]赵莲华,李清,林苋等.黄芪多糖协同顺铂对人肝癌细胞的杀伤作用[J].实用癌症杂志,2005,20(1)：34-35.
[45]黄波.CD4+T细胞抗肿瘤作用[J].国外医学,肿瘤学分册,2000,2：75-76.
[1]邵佳,骆殊.黄芪对免疫系统的作用研究进展[J].北京中医药,2008,27(4)：306-308.
[2]中华人民共和国卫生部药典委员会.中华人民共和国药典[M].广州：广东科技出版化学工业出版牡,2005,271.
[3]温燕梅.黄芪的化学成分研究进展[J].中成药,2006,28(6)：879-883.
[4]CHEN Guohui, HUANG Wenfeng.Progress in pharmacological effects of compo-sitions of As tragalusmembranaceus[J].Chinese Journal of New Drugs 2008.17 (1):1482-1485.
[5]张冬青,汪德清.黄芪总黄酮生物学活性作用研究进展[J].中国中药杂志,2010,35(2)：253-256.
[6]刘晓茵.黄芪的免疫功能调节作用研究概况[J].长春医学,2007,5(3)：64-70.
[7]张玉婷.黄芪现代药理作用与血液病分析[J].实用中医内科杂志,2007.21(2)：14-15.
[8]孙大业,郭艳林,马力耕.细胞信号转导[M].北京：科学出版社,1998：286.
[9]吴宝明,李俊.黄芪多糖在免疫调节中的作用[J].安徽医药,2008,112(7)577-579.
[10]刘敏,欧阳静萍,吴珂等.黄芪多糖对KKAy小鼠骨骼肌蛋白激酶B丝氨酸磷酸化的影响[J].武汉大学学报,2006,27(2)：135-139.
[11]Seo JB,Im JG,Goo JM.Comparison of contrast-enhanced ctangiography and gado-liniumenhanced MR angiography in the detection of subsegment alsized pu-lmonary embolism. An experimental study in a pig model [J].Acta Radio,12003, 44 (4):403-410.
[12]高建峰.黄芪多糖对小鼠免疫细胞NO2cGMP信号系统的效应[J].畜牧与兽医,2008,40(5)：56.
[13]WEI X,ZHANG J.Astrgalusmongholiusand poly gonummultiflorun sprotective f-unction against cyclophoshamide inhibitory effect on thymns[J].Am JChinMed, 2004,32(5):669-680.
[14]Cho WC,Leung KN.In vitro and in vivo immuno-modulating and immuno restor-ative effects of Astragalusmembra naceus[J].Ethnopharmacol,2007,113(1):132-141.
[15]王栓秀,王福禄.黄芪多糖对机体细胞免疫应答影响的研究进展[J].现代中西医结合杂志,2008,17(28)：4505-4506.
[16]翁玲,刘彦,刘学英等.黄芪多糖粉针剂对小鼠脾细胞分泌细胞因子及NK杀伤能力的影响[J].中医药学刊,2003,21(9)：1522-1524.
[17]姚金凤,王志新,张晓勇等.黄芪多糖对小鼠腹腔巨噬细胞免疫功能的调节作用研究[J].河南大学学报,2005,24(1)：34-36.
[18]龚非力.医学免疫学[M].北京：科学出版社,2004,171.
[19]窦晓兵,史变谦.黄芪多糖定向诱生脐血来源树突状细胞及其对T细胞增殖作用的研究[J].中国免疫学杂志,2007,23(6)：544.
[20]颜培宇.黄芪多糖注射液对免疫功能低下小鼠血清IL-4和IFN-4影响的实验研究[J].内蒙古中医药,2007,10(3)：35-36.
[21]窦肇华,张远强,郭顺根.免疫细胞与疾病[M].北京：中国医药科技出版社,2004,9(1)：771.
[22]Orange DE,Jegathesan M,Blachere NE,etal. Effective anti-gen cross presentation by prostate cancer patients dendriticcells implications for prostate cancer immu-notherapy[J].Prostate Cancer Prostatic Dis,2004,7(1):63-72.
[23]HommaS,MataiK,IrieM,OhnoT,etal.Immuno therapy using fusion sofautologous dendritic cells and tumor cells howed effective clinical response in a patient with advanced gastric carcinoma[J].JG astroenterol,2003,38(10):989-994.
[24]Buatois V, Baillet M, Becart S, etal.MHC class Ⅱ pep-tide complexes in dendritic cell lipid microdomains initiate the CD4 TH1 phenotype[J].Immunol,2003,171 (11):5812-5819.
[25]Zeid NA, Muller HK.S1000 positive dendritic cells in human lung tumors as so citated with cell differentiation and enhanced survival[J].Pathology,1993,25 (1):338-43.
[26]Zhang WP, Hel,Cao XT.Enhanced the rapeutic efficacy of tumor RNA pulsed de-ndrtic cell safter genetic modification with lympho cat actin[J].Chin Med,1999, 79(3):170-176.
[27]Shimizu K,Fields RC,Giedlin M, etal.System icad ministration of interleukin en-hances the therapeutic efficacy of dendritic cell based tumor vaccines[J].Proc Na-tl A cad SciUSA,1999,96(5):2268-2273.
[28]SHAO P,ZHAO LH,ZHI C,etal.Regulation on maturation and function of dendri-tic cells by Astragalusmongholicus polysaccharides[J].Int Immuno pharmacol, 2006,6(7):1161-1166.
[29]Ardavin C, Amigorena S, Reis e, et al.Denditric Cell simmounobilogy and cancer immunotherapy[J].Immunity,2004,20(l):17.
[30]董晓辉,董竞成.黄芪注射液增强树突细胞的抗肺癌作用[J].中国实验方剂学杂志,2005,11(1)：25-28.
[31]邵鹏,赵鲁杭.黄芪多糖对树突状细胞表型及功能成熟的影响[J].中华生物学和免疫学杂志,2006,26(7)：637-640.
[32]黄小英,刘端勇,赵海梅.黄芪多糖调节免疫作用研究进展[J].江西中医学院学报,2008,20(4)：75-77.
[33]D Bensky,Steven Claver.Chinese Herbal Medicine,materialMedic3rd Edition[M]. Eastland Press,2004,21(5)77-78.
[34]娄晓芬.黄芪多糖对有核细胞分泌造血因子的影响[J].中药新药与临床药理,2003,14(5)：310-312.
[35]项杰,王育斌,徐涛等.黄芪多糖在宿主抵抗李斯特菌中的作用[J].武汉大学学报,2007,28(6)：741-743.
[36]刘莎.黄芪的免疫调节作用及临床应用[J].国际中医中药杂志2006；28,(4)：203.
[37]李春霞.黄茂对同种移植排斥中CD+4CD2+5T细胞及FxoP3的影响[J].山东大学学报,2006,44,(8)：760-764.
[2]Pui CH,Campana D,Evans WE.Childhood aeute lymphoblastie leukaemia-current Statusand future perspectives[J].Laneet Onco,2001,2:597-607.
[3]Schrappe M,Reiter A,Zimmermann M,et al.Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study groupfrom 1981 to 1995[J].Leukemia,2000,14:2205-2222.
[4]Metzger ML,Howard SC,Ligia CF,et al.Out come of childhood aeute hoblastic ly-mpleukaemia in resouree-poor countries[J].Laneet,2003,362:706-708.
[5]Eden T,Pui CH,Sehrappe M,etal.All children have a right to full aeeess to Treatm-ent for eaneer[J].Lancet,2004,364:1121-1122.
[6]Lilleyman J.Simple deliverable the rapy needed for childhood leukaemia[J].Lanc-et,2003,36(2):676-677.
[7]Pui CH,Relling MV,Doing JR.Aeute lymphoblastie leukaemia[J].NEng Med, 2004,350:1535-1548.
[8]Nandakumar A,Anantha N,Venugopal T,et al.Descriptive epidemiology of Lymp-hoid and haemopoietic malignaneies in Bangalore,India[J].Int Cancer,1995,63: 37-42.
[9]Howard SC,Pedrosa M,Lins M,etal.Establishment of a Pediatric oneology and Pr-ogram out comes of childhood aeute lymphoblastie leukemia in a resourcepoor a-rea[J].JAMA,2004,291:2471-2475.
[10]郑胡铺.儿童急性淋巴细胞白血病治疗进展[J].实用儿科临床杂志,2007,22(3)：167-169.
[11]Mazur B,Szczepa ski T,Karpe J,et al. Decreased numbers of CD4+T lymphocytes in peripheral blood aftertreatment of childhood acute lymphoblastic leukemia[J]. Leuk Res,2006,30(1):33-36.
[12]Winiek NJ,Carroll WL,Hunger SP.Childhood leukemia new advances and chall-enges[J].The New England Journal of Medieine,2004,351(6):601-603.
[13]苏凤哲.中医药治疗急性白血病临床探讨[J].世界中西医结合杂志,2007,2(8)：435-437.
[14]Kosmidis S, Baka M, Bouhoutsou D, et al. Longitudinal assessment of immunol-ogical status and rate of immune recovery following treatment in children with ALL[J],Pediatr Blood Cancer,2008,50(3):528-532.
[15]朱小玉,张祥忠,钟雪云,等.参芪扶正注射液对恶性肿瘤化疗患者造血及免疫功能的影响[J].中国中西医结合杂志,2010,30(2)：205-207.
[16]Pui CH,EvansWE.Treatment of acute lymphoblastie leukemia[J].NEng Med,200-6,354:166-178.
[17]Armitage JO.Tsrgeted therapy and hematological malignaney[J].Target Oncol,2-009,4(1):1-2.
[18]Lee JJ,Kook H,Park MS,et al.Immunotherapy using autologous monoeylederived dendritic cell spulsed with leukemie cell lysates for acute myeloid leukemia rel-apse after autologous peripheral blood stem cell transplantation[J].Clin Aphere-sis,2004,19(3):66-70.
[19]CHEN Guohui, HUANG Wenfeng.Progress in pharmacological effects of compo-sitions of As tragalusmembranaceus Chinese Journal of New Drugs[J].2008,17(1): 1482-1485.
[20]张冬青,汪德清.黄芪总黄酮生物学活性作用研究进展[J].中国中药杂志,2010,35(2)：253-256.
[21]蔡莉.黄芪多糖研究现状与进展[J].中国肿瘤临床,2007,34(15)：896-899.
[22]孔令梅.黄芪的免疫调节作用[J].内蒙古医学杂志,2007,39(1)：74-78.
[23]刘莎,符州.黄芪的免疫调节作用及临床应用[J].国际中医中药杂志,2006,28(4)：203-205.
[24]董菊,吕海燕,毛静娥等.黄芪注射液在肿瘤化疗中增效减毒作用的Meta分析[J].中医药,2010,16(3)：87-92.
[25]赵美蓉,周洁.黄芪多糖对恶性肿瘤化疗后骨髓抑制的影响[J].天津中医药.2007,24(2)：114-115.
[26]蔡莉,朱江.黄芪多糖研究现状与进展[J].中国肿瘤临床,2007,34(15)：896-900.
[27]汪德清,沈文梅,田亚平等.黄芪提取成分对氧自由基作用的影响[J].中国药理学通报,1994,10(2)：129-132.
[28]洪介民,王培训,邱健行等.黄芪多糖对小鼠巨核系祖细胞的影响[J].中药新药与临床药理,1998,9(3)：161-163.
[29]夏星,申萍,严翠娥等.黄芪多糖在长期骨髓细胞培养中支持体外造血的作用[J].中国中医药信息杂志,2003,10(4)：27-28.
[30]翁玲,刘学英,刘彦等.黄芪多糖对小鼠骨髓及外周血造血干细胞的增殖及动员作用[J].基础医学与临床,2003,23(3)：306-309.
[31]张仲平,洪介民.黄芪多糖对体外人骨髓造血细胞生成的影响[J].中药药理与临 床,2000,16(1)：16-17.
[32]哈敏文,李振,何安光等.黄芪合剂防治化疗性骨髓抑制的实验研究[J].中国医科大学报,1997,26(5)：449-452.
[33]袁万青,田涛.黄芪注射液配合化疗治疗白血病52例[J].陕西中医,2008,29(12)：1622.
[34]邓成珊主编.当代中西医结合血液病学[M].北京：中国医药科技出版社,1997：362.
[35]黄智芬.黄芪注射液配合西药治疗肿瘤化疗后血小板减少症30例[J].中国中医药科技,2010,23(1)：17.
[36]Pession A,Rondelli R,Basso G, et al.Treatment and long-term results in children with acute myeloid leukemia treated according to the AIEOPAML protocols Leukemia[J].2005,19:2043-2053
[37]韩晓红,石远凯,冯奉仪等.流式细胞术分析肿瘤患者免疫功能变化[J].实用肿瘤杂志,1999,14(5)：273-275.
[38]Cho WC,Leung KN.In vitro and in vivo immuno-modulating and immuno res-torative effects of Astragalusmembra naceus[J].Ethnopharmacology.2007,113(1): 132-141.
[39]Deepak PA,et al.Cancer Immunol Immunother tumor immunotherapy[J],2006,55: 1135.
[40]曹琰,严媚.小儿急性白血病治疗前后机体细胞免疫的变化[J].中国小儿血液与肿瘤杂志,2009,14(2)：82-84.
[41]王栓秀,王福禄.黄芪多糖对机体细胞免疫应答影响的研究进展[J].现代中西医结合杂志,2008,17(28)：4505-4506.
[42]刘莎.黄芪的免疫调节作用及临床应用[J].国际中医中药杂志,2006,28,(4)：203.
[43]姚金凤,王志新,张晓勇等.黄芪多糖对小鼠腹腔巨噬细胞免珠抑瘤作用及其机制[J].中国医院药学杂志,2005,25(10)：923.
[44]赵莲华,李清,林苋等.黄芪多糖协同顺铂对人肝癌细胞的杀伤作用[J].实用癌症杂志,2005,20(1)：34-35.
[45]黄波.CD4+T细胞抗肿瘤作用[J].国外医学,肿瘤学分册,2000,2：75-76.
[1]邵佳,骆殊.黄芪对免疫系统的作用研究进展[J].北京中医药,2008,27(4)：306-308.
[2]中华人民共和国卫生部药典委员会.中华人民共和国药典[M].广州：广东科技出版化学工业出版牡,2005,271.
[3]温燕梅.黄芪的化学成分研究进展[J].中成药,2006,28(6)：879-883.
[4]CHEN Guohui, HUANG Wenfeng.Progress in pharmacological effects of compo-sitions of As tragalusmembranaceus[J].Chinese Journal of New Drugs 2008.17 (1):1482-1485.
[5]张冬青,汪德清.黄芪总黄酮生物学活性作用研究进展[J].中国中药杂志,2010,35(2)：253-256.
[6]刘晓茵.黄芪的免疫功能调节作用研究概况[J].长春医学,2007,5(3)：64-70.
[7]张玉婷.黄芪现代药理作用与血液病分析[J].实用中医内科杂志,2007.21(2)：14-15.
[8]孙大业,郭艳林,马力耕.细胞信号转导[M].北京：科学出版社,1998：286.
[9]吴宝明,李俊.黄芪多糖在免疫调节中的作用[J].安徽医药,2008,112(7)577-579.
[10]刘敏,欧阳静萍,吴珂等.黄芪多糖对KKAy小鼠骨骼肌蛋白激酶B丝氨酸磷酸化的影响[J].武汉大学学报,2006,27(2)：135-139.
[11]Seo JB,Im JG,Goo JM.Comparison of contrast-enhanced ctangiography and gado-liniumenhanced MR angiography in the detection of subsegment alsized pu-lmonary embolism. An experimental study in a pig model [J].Acta Radio,12003, 44 (4):403-410.
[12]高建峰.黄芪多糖对小鼠免疫细胞NO2cGMP信号系统的效应[J].畜牧与兽医,2008,40(5)：56.
[13]WEI X,ZHANG J.Astrgalusmongholiusand poly gonummultiflorun sprotective f-unction against cyclophoshamide inhibitory effect on thymns[J].Am JChinMed, 2004,32(5):669-680.
[14]Cho WC,Leung KN.In vitro and in vivo immuno-modulating and immuno restor-ative effects of Astragalusmembra naceus[J].Ethnopharmacol,2007,113(1):132-141.
[15]王栓秀,王福禄.黄芪多糖对机体细胞免疫应答影响的研究进展[J].现代中西医结合杂志,2008,17(28)：4505-4506.
[16]翁玲,刘彦,刘学英等.黄芪多糖粉针剂对小鼠脾细胞分泌细胞因子及NK杀伤能力的影响[J].中医药学刊,2003,21(9)：1522-1524.
[17]姚金凤,王志新,张晓勇等.黄芪多糖对小鼠腹腔巨噬细胞免疫功能的调节作用研究[J].河南大学学报,2005,24(1)：34-36.
[18]龚非力.医学免疫学[M].北京：科学出版社,2004,171.
[19]窦晓兵,史变谦.黄芪多糖定向诱生脐血来源树突状细胞及其对T细胞增殖作用的研究[J].中国免疫学杂志,2007,23(6)：544.
[20]颜培宇.黄芪多糖注射液对免疫功能低下小鼠血清IL-4和IFN-4影响的实验研究[J].内蒙古中医药,2007,10(3)：35-36.
[21]窦肇华,张远强,郭顺根.免疫细胞与疾病[M].北京：中国医药科技出版社,2004,9(1)：771.
[22]Orange DE,Jegathesan M,Blachere NE,etal. Effective anti-gen cross presentation by prostate cancer patients dendriticcells implications for prostate cancer immu-notherapy[J].Prostate Cancer Prostatic Dis,2004,7(1):63-72.
[23]HommaS,MataiK,IrieM,OhnoT,etal.Immuno therapy using fusion sofautologous dendritic cells and tumor cells howed effective clinical response in a patient with advanced gastric carcinoma[J].JG astroenterol,2003,38(10):989-994.
[24]Buatois V, Baillet M, Becart S, etal.MHC class Ⅱ pep-tide complexes in dendritic cell lipid microdomains initiate the CD4 TH1 phenotype[J].Immunol,2003,171 (11):5812-5819.
[25]Zeid NA, Muller HK.S1000 positive dendritic cells in human lung tumors as so citated with cell differentiation and enhanced survival[J].Pathology,1993,25 (1):338-43.
[26]Zhang WP, Hel,Cao XT.Enhanced the rapeutic efficacy of tumor RNA pulsed de-ndrtic cell safter genetic modification with lympho cat actin[J].Chin Med,1999, 79(3):170-176.
[27]Shimizu K,Fields RC,Giedlin M, etal.System icad ministration of interleukin en-hances the therapeutic efficacy of dendritic cell based tumor vaccines[J].Proc Na-tl A cad SciUSA,1999,96(5):2268-2273.
[28]SHAO P,ZHAO LH,ZHI C,etal.Regulation on maturation and function of dendri-tic cells by Astragalusmongholicus polysaccharides[J].Int Immuno pharmacol, 2006,6(7):1161-1166.
[29]Ardavin C, Amigorena S, Reis e, et al.Denditric Cell simmounobilogy and cancer immunotherapy[J].Immunity,2004,20(l):17.
[30]董晓辉,董竞成.黄芪注射液增强树突细胞的抗肺癌作用[J].中国实验方剂学杂志,2005,11(1)：25-28.
[31]邵鹏,赵鲁杭.黄芪多糖对树突状细胞表型及功能成熟的影响[J].中华生物学和免疫学杂志,2006,26(7)：637-640.
[32]黄小英,刘端勇,赵海梅.黄芪多糖调节免疫作用研究进展[J].江西中医学院学报,2008,20(4)：75-77.
[33]D Bensky,Steven Claver.Chinese Herbal Medicine,materialMedic3rd Edition[M]. Eastland Press,2004,21(5)77-78.
[34]娄晓芬.黄芪多糖对有核细胞分泌造血因子的影响[J].中药新药与临床药理,2003,14(5)：310-312.
[35]项杰,王育斌,徐涛等.黄芪多糖在宿主抵抗李斯特菌中的作用[J].武汉大学学报,2007,28(6)：741-743.
[36]刘莎.黄芪的免疫调节作用及临床应用[J].国际中医中药杂志2006；28,(4)：203.
[37]李春霞.黄茂对同种移植排斥中CD+4CD2+5T细胞及FxoP3的影响[J].山东大学学报,2006,44,(8)：760-764.